Introduction to Astellas’ Pioneering Regulatory Submission According to the news (News | Astellas Pharma Inc.) released by Astellas Pharma on Feb/05/2025, they have submitted a manufacturing and marketing approval application in Japan for avacincaptad pegol (ACP), branded as IZERVAY, targeting geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Notably, this application is under Japan’s […]